Avoiding unanticipated adverse effects of recombinant human bone morphogenetic protein-2 therapy in craniofacial surgery with experiences from spinal applications.
Smoljanovic
Tomislav
T
Janjanin
Sasa
S
Bojanic
Ivan
I
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects*; D001862:Bone Resorption / Q000139:chemically induced; D019465:Craniofacial Abnormalities / Q000601:surgery*; D006801:Humans; D009999:Ossification, Heterotopic / Q000139:chemically induced; D010012:Osteogenesis / Q000187:drug effects*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012886:Skull / Q000601:surgery*; D013115:Spinal Canal / Q000187:drug effects; D013131:Spine / Q000601:surgery; D016212:Transforming Growth Factor beta / Q000009:adverse effects / Q000627:therapeutic use*
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2